Improve Human Health to Preserve Patients’ Dignity

Asieris announces NMPA has accepted the New Drug Application for APL-1706, an Imaging Drug for Diagnosing and Management of Bladder Cancer

Asieris’First Product Dipaite Achieves Commercialization and Launches in China, First Prescription Issued in Shanghai

Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress

Asieris to Unveil First-ever Results of the Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the 2023 SIU Annual Meeting

The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC